Alzheimer’s disease stands as the leading cause of dementia, impacting over 7 million individuals in the United States alone. While there exist treatments that can decelerate its progression, these therapies primarily address symptoms and do not offer a cure.
Daniel Schultz, a former postdoctoral fellow at the Vanderbilt University Warren Center for Neuroscience Drug Discovery, emphasises that “Alzheimer’s is a condition that remains recalcitrant to the scientific community’s attempts at developing a cure or preventative treatment.” This highlights a pressing need for new therapeutics not only for Alzheimer’s but also for a multitude of neurological diseases and neurodevelopmental disorders. A significant barrier to achieving this goal lies in the existing gaps in our understanding of the underlying biology of these conditions.
Despite the identification of certain genes and proteins associated with various neurological disorders, studying their functions remains a challenge, particularly when researchers lack the means to modulate their activity.
Tool Compounds: Advancing Brain Research
One promising avenue for enhancing our understanding of protein functions is through the use of “tool compounds.” These compounds interact with specific proteins to modulate their activity, either increasing or decreasing it. Although many tool compounds may not be suitable as drug candidates due to potential off-target effects and toxicities, they play a crucial role in facilitating the exploration of protein functions, marking an essential step in the journey towards developing effective treatments.
A recent study published in ACS Chemical Neuroscience by Schultz and Lauren Parr, a Ph.D. student in the Department of Pharmacology, reports the development of a tool compound that selectively inhibits TAOK-1, a protein linked to Alzheimer’s that has not been thoroughly investigated due to a lack of suitable compounds. The study is titled “Discovery of VU6083859, a TAOK1 Selective Inhibitor, and VU6080195, a pan-TAOK Activator.”
Insights from the Drug Discovery Pipeline
This research was primarily conducted within the Vanderbilt University Warren Center for Neuroscience Drug Discovery (WCNDD), under the leadership of Executive Director Craig Lindsley. The WCNDD, a clinical-stage biotech start-up, currently boasts a drug discovery pipeline with five compounds in Phase I clinical trials. It also plays a foundational role in the new Vanderbilt Institute for Therapeutic Advances, an innovative drug discovery institute led by Lindsley.
For this study, Schultz, Parr, and their colleagues synthesised a diverse library of compounds, each with slight variations, to evaluate their activity against TAOK-1 and their drug-like properties. Schultz remarked, “This project showcased the strength of the WCNDD’s drug discovery infrastructure.” The collaborative efforts resulted in the identification of the first selective inhibitor of TAOK-1, named VU6083859, which may serve as a starting point for future Alzheimer’s disease treatments.
New Findings and Future Directions
Another compound, VU6080195, emerged as a standout. This compound acts as an activator of all three proteins in the TAOK family, an unexpected and serendipitous finding. Schultz expressed enthusiasm about this discovery, stating, “Our understanding of TAOK proteins largely centres around their inhibition, so we are excited at the prospect of studying the neurological effects of increasing their activity.” This underscores the unpredictable nature of scientific research, where unexpected results can lead to new avenues of inquiry.
With the introduction of these two novel tool compounds, there is an opportunity to rekindle interest in the TAOK family, which has been relatively understudied in vivo. Enhanced understanding of the biological mechanisms underlying diseases can improve our prospects for developing effective treatments. The availability of these compounds allows neuroscientists to delve deeper into a protein family associated with Alzheimer’s and other neurological conditions, potentially laying the groundwork for innovative therapies or even a cure.
Publication details: Daniel C. Schultz et al, Discovery of VU6083859, a TAOK1 Selective Inhibitor, and VU6080195, a pan-TAOK Activator, ACS Chemical Neuroscience (2026). DOI: 10.1021/acschemneuro.5c00906
Journal information: ACS Chemical Neuroscience
Key medical concepts: Alzheimer’s Disease
Clinical categories: Neurology, Clinical pharmacology